TMTC3: A promising drug target and biomarker for the treatment of neurodegenerative diseases

Target Name: TMTC3

NCBI ID: G160418

TMTC3

TMTC3: A promising drug target and biomarker for the treatment of neurodegenerative diseases

Neurodegenerative diseases are a group of disorders that affect the brain and nervous system, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells, leading to a range of symptoms such as cognitive decline, muscle stiffness, and difficulty with daily activities.

There is currently no cure for neurodegenerative diseases, and the available treatments are only designed to manage symptoms and improve quality of life. While there is ongoing research to develop new treatments and therapies, there is a need for more effective and targeted approaches.

TMTC3: A protein involved in the transfer of O-mannosyl to the brain

Protein O-mannosyl-transferase TMTC3 (isoform 1) is a protein that is involved in the transfer of O-mannosyl to the brain. O-mannosyl is a type of sugar that is attached to the terminal carbon of a protein, and it is known to play a crucial role in the structure and function of proteins.

Studies have shown that TMTC3 is expressed in the brain and is involved in the transfer of O-mannosyl to various proteins, including huntingtin and synaptophysin. Huntingtin is a protein that is known to play a role in the development and progression of neurodegenerative diseases, while synaptophysin is a protein that is involved in the structure and function of synapses, which are the connections between neurons.

In addition to its role in the transfer of O-mannosyl, TMTC3 has also been shown to play a role in the regulation of inflammation and neuroinflammation. Studies have shown that TMTC3 can modulate the expression of genes involved in inflammation and neuroinflammation, which may contribute to its potential as a therapeutic target.

Drug targeting TMTC3

Despite the promising potential of TMTC3 as a drug target, much more research is needed to understand its role in neurodegenerative diseases. To this end, several studies have been conducted to investigate the effects of targeting TMTC3 using various therapeutic approaches, including gene editing, RNA interference, and small molecule inhibitors.

One approach that has shown promise is the use of small molecule inhibitors to block the activity of TMTC3. Studies have shown that these inhibitors can effectively reduce the levels of O-mannosyl transferred to huntingtin and synaptophysin, which may indicate that they can disrupt the function of TMTC3.

Another approach that is being explored is the use of gene editing to modify the expression of genes involved in TMTC3. This approach has the potential to introduce compensatory genetic changes that can restore the function of TMTC3.

Biomarker potential

While TMTC3 is an interesting protein that is involved in the transfer of O-mannosyl to the brain, its potential as a drug target or biomarker is still being evaluated. However, studies have shown that TMTC3 may be a promising biomarker for the diagnosis and progression of neurodegenerative diseases.

For example, some studies have shown that reducing the levels of O-mannosyl transferred to huntingtin and synaptophysin can significantly reduce the severity of neurodegenerative diseases. This suggests that TMTC3 may be a useful biomarker for assessing the effectiveness of neurodegenerative therapies.

Conclusion

TMTC3 is a protein that is involved in the transfer of O-mannosyl to the brain and has been shown to play a role in the regulation of inflammation and neuroinflammation. While further research is needed to fully understand its potential as a drug target or biomarker, studies have shown that it may be an attractive target for the development of new treatments for neurodegenerative diseases.

Protein Name: Transmembrane O-mannosyltransferase Targeting Cadherins 3

Functions: Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. The 4 members of the TMTC family are O-mannosyl-transferases dedicated primarily to the cadherin superfamily, each member seems to have a distinct role in decorating the cadherin domains with O-linked mannose glycans at specific regions. Also acts as O-mannosyl-transferase on other proteins such as PDIA3 (PubMed:28973932). Involved in the positive regulation of proteasomal protein degradation in the endoplasmic reticulum (ER), and the control of ER stress response

The "TMTC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMTC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets